DNAJC21 Mutations Link a Cancer-Prone Bone Marrow Failure Syndrome to Corruption in 60S Ribosome Subunit Maturation by Tummala, H et al.
ARTICLE
DNAJC21 Mutations Link a Cancer-Prone
Bone Marrow Failure Syndrome
to Corruption in 60S Ribosome Subunit Maturation
Hemanth Tummala,1 Amanda J. Walne,1 Mike Williams,2 Nicholas Bockett,1 Laura Collopy,1
Shirleny Cardoso,1 Alicia Ellison,1 Rob Wynn,3 Thierry Leblanc,4 Jude Fitzgibbon,5 David P. Kelsell,6
David A. van Heel,1 Elspeth Payne,7 Vincent Plagnol,8 Inderjeet Dokal,1,9 and Tom Vulliamy1,9,*
A substantial number of individuals with bone marrow failure (BMF) present with one or more extra-hematopoietic abnormality. This
suggests a constitutional or inherited basis, and yet many of them do not fit the diagnostic criteria of the known BMF syndromes.
Through exome sequencing, we have now identified a subgroup of these individuals, defined by germline biallelic mutations in
DNAJC21 (DNAJ homolog subfamily C member 21). They present with global BMF, and one individual developed a hematological can-
cer (acute myeloid leukemia) in childhood. We show that the encoded protein associates with rRNA and plays a highly conserved role in
the maturation of the 60S ribosomal subunit. Lymphoblastoid cells obtained from an affected individual exhibit increased sensitivity to
the transcriptional inhibitor actinomycin D and reduced amounts of rRNA. Characterization of mutations revealed impairment in in-
teractions with cofactors (PA2G4, HSPA8, and ZNF622) involved in 60S maturation. DNAJC21 deficiency resulted in cytoplasmic accu-
mulation of the 60S nuclear export factor PA2G4, aberrant ribosome profiles, and increased cell death. Collectively, these findings
demonstrate that mutations in DNAJC21 cause a cancer-prone BMF syndrome due to corruption of early nuclear rRNA biogenesis
and late cytoplasmic maturation of the 60S subunit.Introduction
Inherited bone marrow failure (BMF) syndromes are a het-
erogeneous group of life-threatening disorders character-
ized by a hematopoietic defect in association with a range
of variable extra hematopoietic features. Recognized syn-
dromes include Fanconi anemia (MIM: 227650),1 dyskera-
tosis congenita (MIM: 305000),2 Shwachman Diamond
syndrome (MIM: 260400),3 and Diamond Blackfan anemia
(MIM: 105650).4 Cells from Fanconi anemia cases exhibit
increased chromosomal breakage due to specific genetic
and/or functional defects causing genome instability.1
Dyskeratosis congenita cases are characterized by diag-
nostic mucocutaneous features such as abnormal skin
pigmentation, nail dystrophy, and leukoplakia together
with the presence of very short telomeres.2 Shwachman
Diamond syndrome is characterized by exocrine pancre-
atic insufficiency, and individuals with Diamond Blackfan
anemia are typically reported to have craniofacial abnor-
malities, including clefting of the lip or palate, thumb ab-
normalities, cardiac malformations, and short stature.5
Importantly, these syndromes are also associated with an
increased cancer risk.
In addition to the well-defined BMF syndromes, we have
accrued a number of cases to our BMF registry that do not
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The A
 2016terized individuals have BMF together with one or more
somatic abnormalities, suggesting a constitutional or in-
herited basis, but do not fulfil the clinical criteria of the
known BMF syndromes. With the advent of whole-exome
sequencing, it is now possible to unify subsets of these
cases through the identification of their underlying genetic
defect. This is the case here, as we identify a cohort of sim-
plex BMF cases harboring biallelic mutations in DNAJC21.
Through characterization of the encoded protein, we
define a cancer-prone BMF syndrome caused by defective
DNAJC21.Material and Methods
Study Approval
All experiments were conducted with the approval of Barts and
The London Hospital. Peripheral blood samples were obtained
with written consent under the approval of our local research
ethics committee (London – City and East).DNA Sequencing and Plasmids
All samples were obtained with informed written consent and the
approval of our local ethics committee. Genomic DNA was ex-
tracted from peripheral blood with Gentra reagents (QIAGEN).
For exome sequencing, 50 ng of genomic DNA underwent library
preparation and exome capture via the Illumina Nextera Rapidon School of Medicine and Dentistry, Queen Mary University of London,
ldren’s Hospital, Birmingham B4 6NH, UK; 3Blood and Marrow Transplant
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Capture Exome kit. Sequencing was performed with the Illumina
HiSeq 2000 system, and 100 bp paired-end reads were generated
and the data processed through the Illumina pipeline. Variants
were called as described previously.6 Resequencing of DNAJC21
was performed as a part of a 32 gene panel and amplified with a
TruSeq Custom Amplicon reagent, which was then prepared for
MiSeq sequencing according to the manufacturer’s instructions
(Illumina). All relevant calls were confirmed by Sanger sequencing.
DNAJC21 wild-type and mutant expression constructs were ob-
tained by standard cDNA cloning and mutagenesis procedures
into peGFP-C1 (Clontech) plasmid.
Nuclear rRNA Co-immunoprecipitation Assay
Dialyzed nuclear extracts from ~106 cells expressing eGFP alone or
eGFP-tagged wild-type and mutant forms of DNAJC21 were sub-
jected to immunoprecipitation with GFP-TRAP agarose beads
(ChromoTek). After incubation and stringent washes, immune
complexes were treated with DNase I (RNase-free) (Fermentas)
for 30 min at 37C in the presence of RNasein (Invitrogen). The re-
actions were stopped by addition of 2.5 mM EDTA and heating for
10 min at 65C. Co-immunoprecipitated RNA was extracted by
Trizol (Invitrogen), purified with RNeasy kit columns (QIAGEN),
and analyzed by qRT-PCR for precursor 45S rRNA using primers
indicated in Table S3.
qRT-PCR
RNA from nuclear extracts was purified with TRIzol reagent (Invi-
trogen) according to themanufacturer’s instructions. Reverse tran-
scription was performed with SuperScript III Reverse Transcriptase
(Invitrogen). qPCR was carried out on a real-time PCR detection
system with SYBR Green (Thermo Fisher) for 45S precursor
rRNA, mature 28S, and 18S rRNA in individual 4, both parents,
and three unrelated control individuals. Data presented is normal-
ized to GAPDH mRNA amounts, and expression of SNORA63 and
SNORA68 was determined as internal standard controls.
RNAi Studies
All siRNA and shRNA experiments were performed on HeLa cells
cultured at 37C in 5%CO2 and DMEM (Cambrex), supplemented
with L-glutamine, 10% fetal calf serum (FCS), and penicillin
and/or streptomycin antibiotics. Transfections of DNAJC21 siRNA
(Sigma, cat. no. EHU103331) were carried out with 50 nM siRNA
and Lipofectamine 2000 (Invitrogen), according to the manufac-
turer’s protocol; a predesigned non-target siRNA (Ambion) was
used as a negative control. Cells were harvested at 72 hr for subse-
quent analysis. Tet-pLKO-puro shRNA-expressing plasmids were
obtained from Addgene and prepared using a protocol adopted
from Addgene7 to generate Tet-pLKO-puro DNAJC21 30 UTR
shRNA-specific clones. The specific shRNA sequences of the
DNAJC21 30 UTR used in this study were obtained from the
RNAi Consortium (TRC MISSION shRNA library) and the RNAi
designer tool from Thermo Fisher. Target sequences are given in
Figure S4A. DNAJC21 30 UTR shRNA expression was induced by
culturing cells in DMEM supplemented with tetracycline (Tet)-
free serum (Clontech) for 72 hr in the presence of the indicated
concentrations of doxycycline (dox; Sigma, Figure S4B) dissolved
in deionized water.
Immunostudies
For co-immunoprecipitation studies, approximately 250 mg cell
lysate was used per immunoprecipitation in cells transfected116 The American Journal of Human Genetics 99, 115–124, July 7, 20with eGFP encoding wild-type and mutant DNAJC21 plasmids.
In brief, 72 hr after transfection, lysates were precleared with
rabbit control IgG (monoclonal SP137, Abcam) and further incu-
bated with 10 ml anti-GFP antibody (Abcam, cat. no. EPR14104)
overnight at 4C. For determination of nucleic-acid-mediated
interaction, cell lysates were initially treated with 40 U DNase I
(RNase-free) or 25 mg/mL RNase A for 30 min at 37C. The next
day, 20 ml Protein A Dynabeads (Thermo Fisher) pre-equilibrated
with immunoprecipitation (IP) buffer (25 mM Tris-HCl [pH 7.9],
5mMMgCl2, 10% glycerol, 0.1%NP-40, 1mMDTT, 13Complete
EDTA-free protease inhibitor cocktail) containing 100mMKCl was
added and gently mixed for 2 hr at 4C. Immune complexes were
washed three times with IP buffer containing 150 mM KCl and
two times with IP buffer containing 100 mM KCl, each for
5 min at 4C. Immunoprecipitates were boiled in SDS-sample
buffer (25 mM TrisHCl [pH 6.8], 2% SDS, 10% glycerol, 0.05% bro-
mophenol blue, 5% 2-mercaptoethanol) for 5 min, separated by
SDS- PAGE, transferred to polyvinylidene membranes, and sub-
jected to western blot analysis with aWesternBreeze Chromogenic
kit (Thermo Fisher, cat. no. WB7106 and WB7104). Antibodies
against DNAJC21 (Abcam, cat. no. ab86434, C terminal epitope
corresponding to amino acids 400–450; Proteintech, cat. no.
23411-1-AP, N terminal epitope corresponding to amino acids
43–288), PA2G4 (Abcam, cat. no. ab119037), ZNF622 (Abcam,
cat. no. Ab57859), and HSPA8 (Abcam, cat. no. EP1513Y) were
used in the study. For immunocytochemical staining, HeLa cells
and IMR-90 cells (primary lung fibroblasts obtained from ATCC
CCL-186) were grown on coverslips, fixed in 4% paraformalde-
hyde, permeabilized with 0.1% Triton X-100 (TX100) in PBS,
quenched in 50 mM NH4Cl, and blocked in 10% goat serum
and 1% BSA in PBS containing 0.05% TX100 for 1 hr. Cells were
incubated with corresponding primary and secondary antibodies
and mounted via vectashield containing DAPI (Vector Labs, cat.
no. H-1200). Images were collectedwith an LSM710 laser scanning
confocalmicroscope (Olympus) under relevant excitation, and the
emitted signals were visualized with ZEN software (Zeiss). Nucle-
olar co-staining was determined by mouse monoclonal antibody
against nucleophosmin (Abcam, cat. no. ab40696) and DNAJC21.Sub-cellular Fractionation
DNAJC21 knockdown and control cells were lysed in ice-cold
HEPES containing 0.1% NP40 and centrifuged at 3,000 rpm, and
the supernatant was collected for extraction of cytoplasmic pro-
tein. The pellet-containing nuclei were briefly washed three
times in ice-cold HEPES containing 0.1% NP40, were added to
the pellet ice-cold radioimmunoprecipitation assay (RIPA) buffer
containing a cocktail of protease and phosphatase inhibitors
(Roche, cat. no. 04693116001), and were sonicated twice for
10 s at 50% pulse to release nuclear proteins. The final mixture
was shaken gently on ice for 15 min, and the nuclear fraction pro-
tein supernatant was obtained by centrifugation at 14,000 g for
15 min. Fractionated lysates were verified with antibodies against
cytoplasmic GAPDH (Abcam, cat. no. EPR16891) and nuclear
TATA binding protein (Abcam, cat. no. EPR3826) by immunoblot-
ting as described above.T Cell Isolation and Culture
Blood samples were obtained from individual 4 and her unaffected
heterozygous parents. Peripheral blood mononuclear cells were
separated with lymphocyte separation medium (Lonza) according
to the manufacturer’s instructions, washed twice with complete16
Table 1. Features of Subjects with Biallelic Mutations in DNAJC21
Subject 1 Subject 2 Subject 3 Subject 4
Genotype (c.) 517C>T 983þ1G>T 94C>G 793G>T
Protein (p.) Arg173* Gly299Alafs*2a Pro32Ala Glu265*
Gender F F M F
Age when sample
received (years)
3 6 12 6
Country of origin France Algeria Pakistan Pakistan
Are parents first
cousins?
Y Y Y N
Bone marrow
failureb
Y Y Y Y
IUGR and/or
short stature
Y Y Yc Y
Microcephaly Y Y N N
Other features N Yd Ye Yf
Chromosomal
breakageg
N N N N
Telomere
lengthh
normal normal normal normal
F, female; M, male; Y, yes; N, no; IUGR, intrauterine growth restriction.
aInferred from splice-site variant.
bThe bone marrow failure was global and was associated with a reduction in all
cell lineages in the peripheral blood (pancytopenia). Subject 3 developed acute
myeloid leukemia, sub-type megakaryocytic (AML-M7).
cGrowth hormone defect.
dDental abnormalities (microdontia), hyperkeratosis, and retinal dystrophy
with poor vision.
eSkin pigmentation abnormalities on feet and dental abnormalities.
fDysphagia and/or oral ulceration.
gAfter treatment with diepoxybutane or mitomycin C.
hMeasured by monochrome multiplex qPCR.9RPMI medium containing 15% FCS, and resuspended at 1$03 106
cells/mL in RPMI-1640 medium and 20% FCS (Invitrogen). T cell
mitosis was stimulated by the addition of 10 mg/mL of phytohae-
magglutinin (PHA; Roche Applied Science). After 48 hr, the me-
dium was replaced with fresh RPMI medium containing
10 units/mL of recombinant human interleukin-2 (Invitrogen)
and harvested after 14 days. Cells were counted on a
NucleoCounter YC-100 automated cell counter (ChaemoMetec).
Epstein-Barr virus (EBV)-infected lymphoblastoid cells (LCLs)
were established and grown in RPMI-1640 medium supplemented
with penicillin and streptomycin, 2 mM L-glutamine, and 20%
(vol/vol) FBS (Invitrogen).
Polysome Analysis
For analysis of monosomes and polysomes, HeLa cells and LCLs
were grown to confluence, harvested 10 min after treatment
with 100 mg/mL cycloheximide (CHX; Sigma), and resuspended
in PBS containing 100 mg/mL CHX. Equal numbers of cells were
lysed in 425 mL of hypotonic buffer (5 mM Tris-HCl [pH 7.5],
2.5 mM MgCl2, 1.5 mM KCl, and 13 protease inhibitor cocktail
[EDTA-free]), with 5 mL of 100 mg/mL CHX, 1 mL of 1 M DTT,
and 100 U of RNase inhibitor. Lysates were vortexed for 5 s,
followed by addition of 25 ml of 10% Triton X-100 (final concen-
tration 0.5%) and 25 mL of 10% sodium deoxycholate (final
concentration 0.5%), and vortexed again for 5 s. Lysates were
then centrifuged at 16,000 g for 2 min, and supernatants wereThe Alayered on 15% to 45% (wt/vol) sucrose gradients. The gradients
were centrifuged at 36,000 rpm for 4 hr at 4C in a Beckman
SW41Ti rotor. The fractionated lysates were serially collected,
and polysome profile peaks were obtained by measuring absor-
bance at 254 nm. Proteins from these fractions were precipitated
with 20% (vol/vol) trichloroacetic acid, separated on SDS–
PAGE gels, and transferred to polyvinylidene membranes for
immunoblotting.
Cell Death and Rescue by Wild-Type DNAJC21
After 72 hr of RNAi treatment, cells were washed in PBS; propi-
dium iodide (PI) was added to the cell suspension to a final con-
centration of 5 mg/mL and analyzed on an LSRII Flow Cytometer
(BD Biosciences). Plasmids encoding WT-eGFPDNAJC21 and
peGFP-C1 alone were transfected into DNAJC21 30 UTR shRNA ex-
pressing stable cell lines. 48 hr after transfection, cells were fluores-
cence-activated cell (FAC) sorted by gating for eGFP, collected, and
re-plated in 96 wells in equal number. It is important to note that
the shRNA system targets the 30 UTR of the endogenous DNAJC21
mRNA. This UTR is absent from the plasmid-derived transcript, re-
sulting in shRNA depletion of the endogenous DNAJC21 only
upon dox induction. DNAJC21 30 UTR shRNA 1 (Figure S3) was
preferred because it showed DNAJC21 knockdown upon dox
induction at a lower concentration, 100 ng/mL.
Structural Analysis of the DNAJC21 p.Pro32Ala
Variant
The J domain crystal structure (PBD: 1FAF) was obtained from the
Protein Data Bank and visualized with Swiss PDB Viewer.8 The pre-
dicted effects of the DNAJC21 p.Pro32Ala substitution were gener-
ated with this program.
Statistics
Analyses were performed with GraphPad Prism 5.0 software
(GraphPad Software). Mann-Whitney U test and one-way
ANOVA with Tukey’s post hoc tests were used when appropriate,
as indicated within the text or figure legends. Data are presented
as the means 5 SEM unless otherwise indicated. A two-tailed
p value of <0.05 was considered significant.Results
Biallelic Mutations in DNAJC21 Cause a BMF
Syndrome
In a cohort of 28 unrelated individuals with BMF and
non-specific somatic features from our BMF registry (Table
S1), we sought an underlying genetic basis through
exome sequencing. Three of these individuals, none of
whom had any family history of disease, were found
tohavehomozygous likelypathogenic variants inDNAJC21
([GenBank: NM_001012339.2] Table 1, Figures 1A and 1B).
Specifically, these were a nonsense variant, c.517C>T,
p.Arg173*, in individual 1, a splice variant, c.983þ1G>T,
in individual 2, and a missense variant, c.94C>G,
p.Pro32Ala, in indivdual 3. Targeted resequencing of
DNAJC21 in a second cohort of 23 similar individuals (Table
S2) identified one further individual (indivdual 4) with
a homozygous nonsense variant, c.793G>T, p.Glu265*
(Table 1). Sanger sequencing of parental DNA revealedmerican Journal of Human Genetics 99, 115–124, July 7, 2016 117
Figure 1. Biallelic Mutations in DNAJC21
(A) Sanger sequencing traces and the genotype of each individual are given. Arrows indicate the mutated nucleotides.
(B) The positions of the alterations caused by the mutations observed in our individuals are shown in the context of the conserved func-
tional domains predicted in the DNAJC21 amino acid sequence. Residue numbers are given for the different domains. J domain refers to
the DNAJ domain that defines this group of proteins; DBINO refers to the DNA-binding domain found on global transcription activator
SNF2L1 proteins and chromatin re-modeling proteins. The frameshift p.Gly299Alafs*2 variant is shown in red as it is predicted to arise
from the deletion of exon 7 due to the splice-site mutation c.983þ1G>T in individual 2.
(C) Conservation of the HPD motif in the J domain of DNAJC21. Alignment of residues 16–50 of the human DNAJC21 J domain with
four other DnaJ proteins was generated with ClustalW. The arrow indicates the proline residue that was mutated in individual 3. The
aligned sequences are human (H.s.) DNAJC21 (UniProt: Q5F1R6), Drosophila melanogaster (D.m.) DNAJ-1 (UniProt: Q53ZT0), rice
(O.s.) Oryza sativa DNAJ homolog (UniProt: Q948S9), Saccharomyces cerevisiae (S.c.) DnaJ-related protein SCJ1 (UniProt: P25303), and
Escherichia coli (E.c.) chaperone protein DnaJ (UniProt: P08622). Asterisks indicate positions that have a single fully conserved residue,
colons indicate conservation between groups of strongly similar properties, and periods indicate conservation between groups of weakly
similar properties.
(D) E. coli DnaJ domain topology (PDB:1FAF) visualized with Swiss PDB Viewer. Ribbon diagram depicts J domain (gray) and position of
HPD motif (orange loop). The hydrogen bonds between residues in the HDP motif are indicated by dotted lines (black). Mimicking the
individual 3 mutant by in silico analysis revealed loss of the proline’s cyclic ring, disrupting hydrogen bonds (dotted line, black), when
substituted with alanine in the J domain.that this variant segregated as an autosomal-recessive trait.
The four individuals with biallelic DNAJC21mutations are
similar in clinical presentation (Table 1): they have global
BMF associated with peripheral pancytopenia and are char-
acterized by intrauterine growth restriction and/or short
stature.Oneof them(individual3)developedacutemyeloid
leukemia, sub-typemegakaryocytic (AML-M7), at the age of
12 years (Table 1).
Three of the variants are predicted to cause loss of func-
tion (LOF, defined here as nonsense or splice variants), and
the transcripts containing these nonsense and predicted
frameshift mutations are likely to undergo nonsense-medi-
ated mRNA decay. In the fourth individual, a missense
variant (p.Pro32Ala) disrupts the highly conserved histi-
dine-proline-aspartic acid (HPD) motif that lies at the heart
of the J domain, which defines a family of proteins (Figures
1B and 1C).10 In silico analysis of the p.Pro32Ala substitu-
tion on the tertiary structure of the E. coli J domain (PDB:
1FAF) reveals the loss of the distinctive cyclic structure of
proline in a loop between two a helices (Figure 1D). This118 The American Journal of Human Genetics 99, 115–124, July 7, 20structural alteration to the HPD motif is likely to disrupt
the interaction of the J domain with its cognate heat shock
protein 70 and the subsequent stimulation of ATPase.11 To
our knowledge, none of the variants have been reported
previously apart from the splice variant (c.983þ1 G>A),
which is present only in the heterozygous state in the
Exome Aggregation Consortium (ExAC) database at an
allele frequency of 5/120,170.
The ExAC database estimates the frequency of LOF
alleles in DNAJC21 (combining frameshift, nonsense, and
splice donor- and acceptor-site variants) at about 0.1%
(123 LOF alleles in ~120,000 chromosomes). Hence, the
frequency of LOF homozygotes and compound heterozy-
gotes is expected to be in the range of one per million in-
dividuals. Not including the likely damaging homozygous
missense variant, the observed frequency of LOF homozy-
gous cases in our combined cohort (3 out of 51 individuals)
significantly exceeds this expectation (binomial test
p < 1010). We conclude that the allelic series of muta-
tions that we have identified here defines a subgroup of16
Figure 2. Nucleolar Localization of DNAJC21 and Its Role in rRNA Biogenesis
(A) DNAJC21 is present in both cytoplasmic (Cy) and nuclear fractions (Nu). Antibody against TBP was used as a control for nuclear frac-
tions. WC, whole cell.
(B) Immunocytochemistry shows the subcellular localization of DNAJC21 in different cell types. A lack of DNAJC21 immunostaining is
observed in T cells from individual 4, whereas the parental T cells stain positive. Nucleophosmin (NPM1) is used as a control. Images
display NPM1 (green), DNAJC21 (red), and DAPI (blue). Scale bar, 20 mm.
(C and D) DNAJC21 translocates to the nucleus after actinomycin D treatment. NPM1 is used as positive control.
(E) LCLs from individual 4 and asymptomatic heterozygous parent controls (1 and 2) were plated in the presence of increasing concen-
trations of actinomycin D for 48 hr and assayed for cell viability by staining with neutral red. Assays were performed in octuplets per
experiment and repeated for a minimum of two independent experiments. Data points represent mean 5 SEM.
(F) Individual 4 LCLs show reduced expression for rRNA in nuclear extracts analyzed when compared to both those of parents and three
unrelated samples as controls. Expression of SNORA63 and SNORA68was determined as internal controls. All genes are normalized rela-
tive to expression of GAPDH mRNA. Data represent mean5 SD, n ¼ 2, performed in triplicates.individuals with constitutional BMF caused by defective
DNAJC21.
DNAJC21 Is Implicated in rRNA Biogenesis
DNAJC21 belongs to the family of DnaJ (heat shock pro-
tein 40) chaperone proteins11 and is ubiquitously ex-
pressed in human tissues (Figure S1). We found that
DNAJC21 was present in both cytoplasm and the nucleus
of HeLa and 293T cells. (Figure 2A) Within the nucleus, it
localized primarily to the nucleolus in three different cell
lines tested (Figure 2B). T lymphocytes obtained from
one affected individual (individual 4) revealed a lack of
DNAJC21 immunoreactivity to an antibody recognizing
an N terminal epitope, whereas the parental control
T cells stained positive (Figure 2B).
To date, little is known about human DNAJC21 apart
from a report that its depletion causes a ‘‘miscellaneous’’ ef-
fect on rRNA processing in HeLa cells.12 To investigate the
possible relationship between DNAJC21 and rRNA, HeLa
cells were treated with low levels (2 nM) of actinomycinThe AD (ActD) that are sufficient to exert its inhibitory effect
on rRNA synthesis.13 This treatment resulted in a translo-
cation of DNAJC21 from the cytoplasm to the nucleus (Fig-
ures 2C and 2D). We also observed that LCLs derived from
individual 4 showed an increased sensitivity to ActD treat-
ment when compared to parent controls (Figure 2E). qRT-
PCR analysis of nuclear RNA extracts obtained from these
cells showed lower rRNA levels in the affected individual
than in both parents and unrelated control individuals
(Figure 2F). These results indicate that DNAJC21 is
involved in rRNA biogenesis.
Given its nucleolar localization and response to ActD,
we sought to investigate a role for DNAJC21 in 45S precur-
sor rRNA binding. We therefore performed native RNA co-
immunoprecipitation experiments on nuclear extracts
from HeLa cells expressing wild-type and mutant forms
of GFP-tagged DNAJC21. Amounts of ectopically expressed
GFP-tagged proteins were established by immunoblotting
with an anti-GFP antibody (Figure 3A). qRT-PCR analysis
on GFP-TRAP immunoprecipitates showed that DNAJC21merican Journal of Human Genetics 99, 115–124, July 7, 2016 119
Figure 3. DNAJC21 Associates with rRNA and Interacts with 60S
Ribosome Maturation Factors
(A) Expression of eGFP-tagged DNAJC21 wild-type and mutants
was detected by immunoblotting with anti-GFP. GAPDH was
used as a loading control.
(B) Immunoprecipitation was performed with GFP-TRAP agarose
beads and nuclear extracts of HeLa cells expressing wild-type
and mutant forms of DNAJC21. Cells expressing EGFP alone
were used as a control for the co-immunoprecipitation. RNA was
extracted from the immunoprecipitates and analyzed by RT-PCR.
Data represent mean 5 SD, n ¼ 2 independent experiments per-
formed in duplicate. *p < 0.05, ***p < 0.0001 Mann-Whitney
U test.
(C) Co-immunoprecipitations were performed in HeLa cells ex-
pressing eGFP or eGFP-DNAJC21. Lysates were treated with
DNase I or RNase A prior to immunoprecipitation where indi-
cated. Co-immunoprecipitated proteins were detected by western
blot analysis with eGFP-, HSPA8-, ZNF622-, and PA2G4-specific
antibodies.
(D) Co-immunopreciptation from cells expressing eGFP-tagged
wild-type and mutant forms of DNAJC21 reveal the variable inter-
action with cofactors involved in 60S ribosome maturation. IN,
10% input; IP, immunoprecipitate; WT, wild-type.associates with the precursor 45S rRNA. The truncated
DNAJC21 mutant (p.Arg173*) failed to bind to precursor
45S rRNA (Figure 3B). Taken together, these results support
the notion that DNAJC21 is indeed a pre-rRNA processing
factor,12 given that it associates with precursor 45S rRNA
and is involved in rRNA biogenesis.120 The American Journal of Human Genetics 99, 115–124, July 7, 20DNAJC21 Interacts with 60S Ribosome Maturation
Factors
The yeast ortholog of DNAJC21, Jjj1 (Figure S2A), has been
studied in some detail. In addition to its role in rRNA pro-
cessing in the nucleus,14 Jjj1 has been shown to act in the
final stages of 60S ribosome subunit maturation in the
cytoplasm.14–19 Specifically, Jjj1 is responsible for the evic-
tion of the 60S nuclear export receptor, Arx1 (human or-
thologs, proliferation-associated protein 2G4 [PA2G4],
also known as Erbb3-binding protein 1 [EBP1], and IRES-
specific cellular transacting factor 45 [ITAF45], Fig-
ure S2B).20–22 In order to execute this function, Jjj1 acts
in concert with Rei1 (human orthologs, zinc finger protein
622 [ZNF622], Figure S2C), binding to the 60S subunit.
Together, Jjj1 and Rei1 recruit Ssa1p (human ortholog,
heat shock 70 kDa protein 8 [HSPA8], Figure S2D) to stim-
ulate ATPase activity. This takes place in the cytoplasm,
allowing Arx1 to recycle back into the nucleus to aid in
further rounds of 60S nuclear export (Figure S3).
To determine whether these interactions also occurr in
humans, we expressed eGFP-tagged wild-type and mutant
forms of DNAJC21 in HeLa cells. Co-immunoprecipta-
tion experiments revealed the predicted interactions of
DNAJC21 with PA2G4, ZNF622, and HSPA8 (Figure 3C).
These interactions were not mediated by nucleic acids
given that they were detected in both DNase-I- and
RNase-A-treated cell lysates (Figure 3C). In contrast, expres-
sion of the truncation mutant (p.Arg173*) revealed no
detectable interaction with any of the aforementioned pro-
teins (Figure 3D). We note that it is likely that in vivo, the
transcript encoding p.Arg173* undergoes nonsense-medi-
ated decay, and the variant is included in these studies as
a negative control. The missense variant (p.Pro32Ala) did
interact with PA2G4 and ZNF622, but failed to interact
with HSPA8 (Figure 3D). This is consistent with studies in
yeast, which have shown that mutation of the HPD motif
in Jjj1 results in loss of interaction with its HSP70 binding
partner, Ssa1p.14,16,18
Because these mutants failed to interact with 60S
maturation factors, we further investigated the role of
DNAJC21 in ribosome biogenesis. Immunostudies re-
vealed a dramatic accumulation of PA2G4 in the cytoplasm
of DNAJC21-knockdown cells as well as T lymphocytes
from individual 4, in comparison to the predominantly
nuclear localization observed in the relevant controls (Fig-
ures 4A–4C). These data suggest that loss of DNAJC21 per-
turbs PA2G4 traffic and is consistent with previous studies
in yeast, which showed that Arx1 fails to traffic back to the
nucleus in strains that lack Jjj1.15,17–19 However, there was
no change in the relative abundance of PA2G4, ZNF622,
and HSPA8 in individual 4 LCLs compared to those
of parent controls (Figure 4D). Sucrose density centrifuga-
tion analysis revealed abnormal polysome profiles in indi-
vidual 4 LCLs, as well as in DNAJC21-knockdown cells, in
comparison to controls (Figure 4E). Furthermore, a stark in-
crease in the amount of PA2G4 bound to 60S and 80S peak
fractions is observed in individual 4 LCLs (Figure 4E).16
Figure 4. Loss of DNAJC21 Impairs Traffic of PA2G4, Corrupting Ribosome Biogenesis
(A–C) Cytoplasmic accumulation of PA2G4 was observed in DNAJC21-knockdown cells and T lymphocytes from individual 4 when
compared to relevant controls. (A) and (C) showDAPI (blue) and PA2G4 (red). Scale bars, 35 mm (A) and 20 mm (C). Panels indicate repre-
sentative images taken from different fields of view in three separate experiments. (B) shows immunoblotting of cytoplasmic (C) and
nuclear (N) fractions.
(D) Immunoblotting of LCL lysates from individual 4 and parental controls for DNAJC21 and 60Smaturation factors HSPA8, PA2G4, and
ZNF622.
(E) Cycloheximide-treated lysates from individual 4 and parent control LCLs, as well as DNAJC21 and non-target siRNA-treated HeLa
cells, were fractionated on 15% to 45% sucrose gradients by ultracentrifugation. Absorbance at 254 nM across the gradient fraction is
shown (top panels). Ribosomal subunit ratios (60S:80S) are indicated. TCA-precipitated proteins from equal aliquots of each fraction
were immunoblotted for PA2G4 and RPL7 as a marker for 60S and 80S subunits and polysomes. Data presented is representative of
two independent experiments (n ¼ 2)Collectively, these observations indicate that human
DNAJC21 plays a prominent role in the maturation of
the 60S ribosome subunit.
Loss of DNAJC21 Disrupts Cell Morphology and
Inhibits Cell Growth
Defective ribosome biogenesis could disrupt protein trans-
lation, impairing cellular growth. In line with this, knock-
down ofDNAJC21 induced cell death in HeLa cells (Figures
5A and 5B). DNAJC21-knockdown cells also exhibited an
unusual morphology with markedly elongated cellular
morphology (Figure 5C). T cells obtained from individual
4 also showed a significant impairment in growth rate after
mitogenic stimulation with phytohemagglutinin and
interleukin-2, relative to parental controls (Figure 5D,
p < 0.001, Student’s t test).
To confirm that the cell death, cytoplasmic accumula-
tion of PA2G4, and altered morphology were a conse-
quence of DNAJC21 deficit, we performed experiments
using a dox-inducible shRNA system that targeted the
30 UTR of DNAJC21. Cell lines expressing DNAJC21
30 UTR shRNAwere transfected with either eGFP-DNAJC21
or the eGFP vector alone. Knockdown of the endoge-
nous protein and the ectopic expression of eGFP-tagged
wild-type DNAJC21 (which escapes the effect of the
shRNA) were verified by immunoblotting (Figure 5E). AsThe Aexpected, re-introduction of wild-type DNAJC21 rescued
cell viability and restored normal PA2G4 traffic and
morphology (Figures 5F and 5G), demonstrating that the
observed effects were a specific consequence of DNAJC21
depletion.Discussion
Although the inherited BMF syndromes have several dis-
tinguishing hallmarks, their heterogeneous presentation
and overlapping features have often confounded their
clinical diagnosis. However, as the underlying disease asso-
ciated genes have been discovered, our understanding of
BMF pathogenesis has improved considerably. Now, in
the era of next-generation sequencing, it is possible to
identify subgroups of cases, unified by their underlying ge-
netic defects. In this study, we have used whole-exome
sequencing to identify a distinct subgroup of individuals
presenting with constitutional BMF characterized by defec-
tive DNAJC21.
We have shown that DNAJC21 associates with precursor
45S rRNA. Cells from affected individuals harboring bial-
lelic DNAJC21 mutations had reduced amounts of precur-
sor 45S and mature 28S rRNA and exhibited increased
sensitivity to ActD, implicating its role in rRNA biogenesis.merican Journal of Human Genetics 99, 115–124, July 7, 2016 121
Figure 5. Loss of DNAJC21 Inhibits Cell
Growth
(A) After 72 hr ofDNAJC21 siRNA by doxy-
cycline (dox) treatment to induce shRNA
targeting the 30 UTR of DNAJC21
(100 ng/mL), whole-cell extracts were sub-
jected to western blot analysis with
DNAJC21- andGAPDH-specific antibodies.
(B) FAC sorting plots show increased cell
death in cells treatedwithDNAJC21 siRNA.
(C) Phase contrast microscopy images of
DNAJC21-RNAi-treated cells exhibiting
abnormal morphology in comparison to
controls. All panels are representative of
images taken from different fields of view
in two separate experiments.
(D) T lymphocytes from individual 4 show
impaired growth as compared to parental
controls. Data represent mean 5 SEM;
***p < 0.001, Student’s t test.
(E) Knockdown of endogenous DNAJC21
by dox administration is detected by
western blotting using a mix of both
DNAJC21 and GFP antibodies in stably
transduced DNAJC21 30 UTR shRNA HeLa
cells. Arrows indicate positions of endoge-
nous DNAJC21 and eGFP control.
(F) Cell viability relative to an untreated
dox () culture was measured by GFP fluo-
rescence. This revealed the rescue of cell
viability in the presence of eGFP-DNAJC21
upon dox induction of the shRNA target-
ing the endogenous transcript. Data repre-
sent mean 5 SEM; **p < 0.01 one-way
ANOVA with Tukey’s post hoc test.
(G) In cells expressing eGFP alone,
confocal imaging revealed cytoplasmic
accumulation of PA2G4 and abnormal
morphology upon dox administration.
However, in cells expressing eGFP-
DNAJC21, no defect in PA2G4 shuttling
to the nucleus or cell morphology was
observed upon dox addition (þ) when
compared to an untreated dox () culture.
Images display eGFP (green) and PA2G4
(red). Panels are representative of images
taken from different fields of view in three
separate experiments. Scale bar, 20 mm.In addition, DNAJC21 participates in coordinating nucleo-
cytoplasmic shuttling of PA2G4, to aid in nuclear export of
the 60S subunit. Our findings from DNAJC21 RNAi studies
in HeLa cells and cells from an affected individual provide
compelling evidence in support of the hypothesis that loss
of DNAJC21 perturbs an essential late cytoplasmic step of
the 60S subunit maturation, thereby corrupting ribosome
biogenesis. Previous studies reported that PA2G4 binds to
FG-repeat nucleoporins through its methionine amino
peptidase activity and aid in 60S nuclear export.23 In eu-
karyotic cells, PA2G4 is shown to regulate diverse func-
tions such as cell growth and differentiation, interaction
with transcription factors,22 ribosome biogenesis, and
rRNA processing20,24 as well as IRES-mediated transla-
tion.21 Based on these reports, it is conceivable that cyto-
plasmic accumulation of PA2G4 in absence of DNAJC21
would affect this wide range of diverse functions in human122 The American Journal of Human Genetics 99, 115–124, July 7, 20cells. Together, our data clearly establish that the function
of DNAJC21 in ribosome biogenesis is highly conserved
from yeast to humans.14–19
Altered or reduced ribosome biogenesis has long been
implicated in BMF syndromes.5 We now add DNAJC21 to
the growing list of ribosomopathies, which are a class of
disease caused by mutations that affect the biosynthesis
and or function of the ribosome.25 Ribosomopathies are
intriguingly enigmatic given that they initially present
with pathognomonic features of too few cells in the
marrow but can (in ~10%–20% of cases) later give rise to
hyper-proliferative disorders such as acute myeloid leuke-
mia.5,26 It is notable that this holds true for one of the
four individuals presented here, although with such a
small number of affected individuals, it is difficult to
extrapolate this proportion to a larger cohort. Although
it is likely that these cancers arise from a selection pressure16
resulting in the acquisition of mutations, we also believe
that a dearth of the 60S ribosome subunit could exert
pressure on cells to use defective ribosomes. Over time,
these cells might become error prone, leading eventually
to transition from a hypo- to a hyper-proliferative pheno-
type.26,27
We have identified two distinct areas of operation of
DNAJC21, one in nucleolar rRNA biogenesis and a second
in cytoplasmic recycling of nuclear export factor PA2G4 for
60S subunit maturation.We note that the yeast ortholog of
human DNAJC21 (Jjj1) acts just upstream of the release of
Tif6 by Sdo1 in 60S maturation28 and that the human
ortholog of Sdo1 is SBDS, the protein defective in Shwach-
man Diamond syndrome.29–32 By analogy with SBDS, it is
therefore more likely that the disease phenotype in our
individuals is caused by the late 60S maturation deficit.
This is also consistent with the suggestion that mutations
that affect the overall structural integrity of the ribosome
are less likely to be tolerated.27
It is striking that two out of the four individuals pre-
sented here have homozygous nonsense variants and we
were unable to detect DNAJC21 in the lymphocytes of an
affected individual. It therefore appears that individuals
who lack DNAJC21 remain viable. This is in contrast to
Shwachman Diamond syndrome cases, where no homozy-
gotes for a recurrent nonsense variant have been reported,
suggesting that null mutations in SBDS are embryonic
lethal.33 We do note, however, that the small numbers of
DNAJC21 cases presented here have global BMF by the
age of 12 years, whereas in Shwachman Diamond syn-
drome, the BMF is more variable and often only involves
an isolated neutropenia.34
In conclusion, our study defines a cancer-prone BMF
syndrome caused by mutations in DNAJC21. Characteriza-
tion of the encoded protein shows that it plays a highly
conserved role in ribosome biogenesis. We have therefore
identified a distinct ribosomopathy, highlighting the sig-
nificance of corrupted ribosomes in the etiology of both
hypo-proliferative and hyper-proliferative disorders.Accession Numbers
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